Background: Hypercholesterolemia is a risk factor for the development of cardiac hypertrophy. Astragaloside IV (AST-IV) possesses cardiovascular protective properties. We hypothesize that AST-IV prevents cardiac remodeling with hypercholesterolemia via modulating tissue homeostasis and alleviating oxidative stress. Methods: The ApoE -/-mice were treated with AST-IV at 1 or 10 mg/kg for 8 weeks. The blood lipids tests, echocardiography, and TUNEL were performed. The mRNA expression profile was detected by real-time PCR. The myocytes size and number, and the expressions of proliferation (ki67), senescence (p16 INK4a ), oxidant (NADPH oxidase 4, NOX4) and antioxidant (superoxide dismutase, SOD) were observed by immunofluorescence staining. Results: Neither 1 mg/kg nor 10 mg/kg AST-IV treatment could decrease blood lipids in ApoE -/-mice. However, the decreased left ventricular ejection fraction (LVEF) and fractional shortening (FS) in ApoE −/− mice were significantly improved after AST-IV treatment. The cardiac collagen volume fraction declined nearly in half after AST-IV treatment. The enlarged myocyte size was suppressed, and myocyte number was recovered, and the alterations of genes expressions linked to cell cycle, proliferation, senescence, p53-apoptosis pathway and oxidant-antioxidants in the hearts of ApoE -/-mice were reversed after AST-IV treatment. The decreased ki67 and increased p16
Introduction
Cardiac hypertrophy is generally recognized as an adaptive response of the myocardium to various intrinsic and extrinsic stimuli, which lead the heart to work harder during conditions of increased workload. Cardiac myocytes initially expand in size and increase their protein synthesis, which result in increasing muscle mass. However, prolonged cardiac hypertrophy causes myocyte disarray, apoptosis and interstitial fibrosis, which cease its compensatory function. Eventually, the myocardial remodeling progresses to ventricular dilatation and heart failure [1, 2] , which is one of the leading causes of mortality in the world. Hypercholesterolemia is regarded as a major risk factor for atherosclerosis and heart disease, and increases all-cause mortality in different epidemiological studies [3] [4] [5] . But little is known regarding the direct effects of hypercholesterolemia on cardiac hypertrophy. Previous prospective longitudinal cohort study showed that hypercholesterolemia, as well as hypertension and obesity, predicted the prevalence of left ventricular (LV) hypertrophy twenty years later in human [6, 7] . Hypercholesterolemia in normotensive, non-diabetic adults was independently associated with mild, concentric LV geometry [7] . Therefore, these clinic studies suggested that hypercholesterolemia played a role in the origin of myocardial remodeling.
The apolipoprotein E-deficient (ApoE −/− ) mouse has been the most widely used animal model for hyperlipidemia and atherosclerosis because it has substantially increased total plasma cholesterol, i.e. hypercholesterolemia, and rapidly develops atherosclerotic lesions similar to those noted in humans [8] . Apart from the obvious vascular phenotype in the ApoE −/− mouse, the cardiac phenotypes, such as cardiac hypertrophy [1, 2, [9] [10] [11] [12] , fibrosis [2, 8] and dysfunction, were also noticed, but not intensively investigated. Besides the ApoE -/-animal model, the study in swine fed a high caloric diet suggested that oxidized cholesterols was closely related to cardiac hypertrophy, dysfunction, and increased epicardial fat thickness [13] . High-cholesterol-fed rabbits presented "cholesterol cardiomyopathy" characterized by systolic and diastolic dysfunction [14] . Cholesterol loading to H9c2 cells induced hypertrophic characteristic features, such as increase in cellular surface area and up-regulated expression of hypertrophic gene markers [15] . More studies have provided evidence that hypercholesterolemia is associated with cardiac hypertrophy, which appears to be influenced by several factors, including increased aortic stiffness, arterial hypertension, age, and a Western-type diet. The precise mechanisms leading to cardiac hypertrophy in the hypercholesterolemia are not clear. There exists substantial evidence demonstrating that hypercholesterolemia induces oxidative and/or nitrative stress in the heart, and in turn oxidative and/or nitrative stress plays a role in several cardiac pathologies in hypercholesterolemia [16] .
The heart constantly renews itself, and a balance between cardiac cell death and regeneration preserves suitable myocyte number, and keeps tissue homeostasis [17] . Cell regeneration, the proliferative activity of cardiomyocytes, is the basis of the heart providing its structural integrity and functional activity [18] [19] [20] [21] . Almost all types of heart disease are based on the cardiomyocytes deficiency, which is caused by lower cell regeneration and/or higher cell death (e.g. necrosis, apoptosis). The damaged cells cannot be replaced by new ones and repaired by scar formation and fibrosis. The survival cardiomyocytes continue to grow mainly by hypertrophy, that is an increase in cell size. Little is known about the detrimental effects of hypercholesterolemia on cardiomyocyte number, size and tissue homeostasis, including myocyte regeneration, senescence and apoptosis.
Astragaloside IV (AST-IV, 3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranosylcycloastragenol), is a monomeric and natural saponin isolated from Astragalusmembranaceus (Fisch.) Bge, which is a traditional Chinese herb widely used in clinical practice and has been demonstrated to be effective in treating various diseases [22, 23] , including cardiovascular diseases [24, 25] . AST-IV possesses diverse cardiovascular protective properties against cardiac hypertrophy [26] [27] [28] [29] [30] , cardiomyocyte apoptosis [29] [30] [31] [32] [33] , myocardial fibrosis [30, [34] [35] [36] , oxidative stress [31, 37] and so on.
Plasma Lipid Levels
For detection of plasma lipid levels, mice were kept from feeding the chow diet but water for 12 hours. After that, they were weighed, and the plasma was collected with heparin lithium anticoagulant tube. The concentrations of plasma lipid levels including total cholesterol (TC), triglycerides (TG), low density lipoprotein-cholesterol (LDL-C) and high density lipoprotein-cholesterol (HDL-C) were measured by an automatic biochemistry analyzer (Beckman Coulte Olympus, CA, USA).
Echocardiography and Cardiac Anatomy
Mice were anesthetized with isoflurane (2-3% induction and 0.5-1.5% maintenance), and then M-mode echocardiographic parameters of left ventricular (LV) in the short axis view at the level of the papillary muscles were measured by a high resolution Micro-Ultrasound system (Vevo 2100, VisualSonics Inc., Toronto, Ontario, Canada). The results of LV diameter and posterior wall thickness were collected during diastole and systole. The left ventricular ejection fraction (LVEF) and fractional shortening (FS) were calculated. After sacrificing, the heart and LV were dissected and weighed to calculate the LV-to-heart weight ratio. Then, the LV was sectioned equally into 2 parts perpendicular to the longitudinal axis of the heart, one was embedded in Tissue-Tek  O.C.T compound (Sakura Finetek USA, Inc., Torrance, CA, USA) to obtain frozen sections for histology study, and the other was frozen rapidly in liquid nitrogen and preserved at -80°C until use.
Myocyte Size and Number
The myocyts size and number were measured according to the method of published papers [17, 38] . Briefly, heart sections were stained with cardiac troponin I (cTnI) antibody (sc-133117, Santa Cruz Biotechnology, Inc., CA, USA) and propidium iodide (PI). Morphometric sampling consisted in counting by confocal microscopy the number of myocyte nuclear profiles in an area of tissue section in which cardiac muscle cells were cut perpendicularly. Endomyocardial and epimyocardial regions of LV were photographed to determine the number of nuclear profiles per unit area of myocardium, N(n)A, and the volume fraction Quantitative RT-PCR Total RNA was extracted from tissue with RNAiso Plus (Takara Bio, Dalian, China) according to the manufacturer's instructions. Total RNA (1 µg) was reverse-transcribed into cDNA using the PrimeScript TM RT reagent kit (Takara Bio, Dalian, China). Then, the cDNA was amplified using SYBR Premix Ex Taq TM (Takara Bio, Dalian, China) under the following conditions: 1 cycle of 94°C for 30 sec, followed by 40 cycles of 94°C for 5 sec, 60°C for 30 sec and 72°C for 30 sec. The primers were synthesized by Sangong Biotech Co., Ltd. (Shanghai, China). All samples were performed in triplicate using a thermal cycler system for nucleic acid amplification (7900, Applied Biosystems, Foster City, CA, USA). The average cycle threshold (Ct) from the triplicate PCRs of the target or internal control gene was calculated first, and then 2 -∆Ct transformation for individual and the mean 2 -∆Ct of the control group were obtained. The 2 -∆∆Ct for each sample was calculated by dividing 2 -∆Ct of individual samples from hypercholesterolemic or AST-IV treated groups by the mean 2 -∆Ct of the control group [39] .
A series of genes related to the cell cycle, proliferation, senescence, p53-dependent apoptosis pathway and oxidants-antioxidants, were tested in this study. The cell cycle regulators at transcriptional level of G1, G1/S transition and G2/M transition were examined, including Cyclin D1, which drives cells from G1 to S, is activated by the cyclin dependent kinase CDK4 [38] . In addition, Cyclin E1 forms a complex with CDK2 and phosphorylates p27
Kip1 (an inhibitor of Cyclin D1), tagging it for degradation, thus promoting expression of Cyclin A2, allowing progression to S phase [40] . During G2, the cyclin B1-cdc2 complex, composed by Cyclin B1 and cdc2, is inactivated by phosphorylation [38] . Genes associated with the cyclin dependent kinase inhibitors (CDKIs), such as CDKN1A (p21 Cip ), CDKN1B (p27 Kip1 ) and CDKN2A (p16 INK4a ), cell proliferation (Ki67, MCM5), and senescence (CDKN2A), were determined. The genes related to p53-dependent apoptosis pathway were examined, including Bax, CDKN1A, TP53, Bcl2 and GADD45A.
Histology and Immunofluorescence Staining
Frozen sections, 8 μm in thickness, were used for immunolabeling. Masson trichrome staining was performed according to standard protocol to determine fibrosis of the LV. Myocytes were labeled by cTnI mouse monoclonal antibody with a M.O.M. immunodetection kit (BMK-2202, Vector Laboratories, Burlingame, CA, USA). Oxidative stress and anti-oxidative stress effects were determined by NADPH oxidase 4 (NOX4, ab133303, Abcam, Cambridge, UK), superoxide dismutase 1 (SOD1, ab13498, Abcam, Cambridge, UK) and superoxide dismutase 2 (SOD2, ab13533, Abcam, Cambridge, UK) staining, respectively. Cycling cells were marked by Ki67 (ab16667, Abcam, Cambridge, UK). To test cellular senescence, sections were exposed to P16
INK4a antibodies (ab108349, Abcam, Cambridge, UK). Alexa Fluor 594 and 488 conjugated secondary antibodies from Life Technologies (A21207 and A21208, Carlsbad, CA, USA) were used to combine with the above-mentioned primary antibodies, respectively. DAPI (H-1200, Vector Laboratories, Burlingame, CA, USA) was used to identify the nuclei. All positive staining cells were counted on 5 nonoverlapping but serial regions from inner layer to outer layer of each LV free wall (× 200 magnification).
In Situ Terminal Deoxynucleotidyl Transferase Mediated dUTP Nick End Labeling (TUNEL)
In situ cell death detection kit (No.11684795910, Roche Applied Science, Branford, CT, USA) with fluorescein was employed and performed principally according to the manufacturer's instructions to detect and quantify apoptosis at single cell level based on labeling of DNA stand breaks. All positive staining cells were counted on 5 non-overlapping but serial regions from inner layer to outer layer of each LV free wall (× 200 magnification). Continuous variables were presented as mean ± SD. The relative change of two groups (including a reference group) is expressed as a percentage of the difference between the values of two groups divided by the value of reference group. Significance between two groups was conducted by Student's t-test. The analysis of variance (ANOVA) and Dunnett's test were employed in multiple comparisons. The chi-square test was used to compare categorical variables. All analyses were managed with SPSS 22.0, and P < 0.05 was considered statistically significant.
Results

AST-IV treatment didn't decrease plasma lipid levels of ApoE
−/− mouse In accord with previous reports [1] , ApoE −/− mouse displayed severe hypercholesterolemia rather than hypertriglyceridemia at 8 weeks of age. The concentrations of TC and LDL-C in KOs were 3.7-fold and 8.7-fold higher, respectively, than those of WTs ( Fig. 1A-B) . Conversely, HDL-C level decreased 23% compared with that of WTs. No significant difference in TG between the two groups was detected ( Fig. 1C-D) . The four plasma lipid levels in KOs reduced from 8 weeks to 16 weeks of age, but TC and LDL-C levels were still significantly higher than those of WTs. HDL-C was significantly lower than that of WTs (P < 0.05). The great variability in the cholesterol levels of ApoE −/− mice with chow diet or Western diet aged from 6 weeks to 40 weeks was also reported previously [8] . After administrated with AST-IV for 8 weeks, the mice in AST-LD and AST-HD groups showed higher plasma TC and LDL-C in comparison with the KOs (Fig. 1A-B) . HDL-C was increased 1.9 times in AST-LD group, compared with that of KOs (P < 0.05). Overall, ApoE −/− mice developed hypercholesterolemia, and treatment with AST-IV for 8 weeks could not decrease the TC and LDL-C levels of ApoE −/− mice.
AST-IV treatment could reduce cardiac mass and size, improve cardiac function of ApoE
−/− mice At 8 weeks of age, heart weight (HW), left ventricular weight (LVW), heart-to-body weight ratio (HW/BW), LVW-to-BW ratio (LVW/BW), and LVW-to-HW ratio (LVW/HW) increased in KOs mice ( Fig. 2A-E) . Meanwhile, LV longitudinal axis (LAX) increased consistently ( Fig. 2F ), resulting in a significant expansion of LV. Besides, differences of these variables became even greater in HW, HW/BW, LAX at 16 weeks of age. All these parameters in AST-HD mice were reduced (HW 24%, LVW 28%, HW/BW 8%, LVW/BW 10%, LVW/HW 5%, LAX 10%), and were not altered in AST-LD except a 20% decrease in LVW, compared with KOs. Echocardiographic measurements responded to the changes of cardiac weights, size and function. At 8 weeks of age, compared with WTs, the increase of left ventricular enddiastolic dimension (LVDd, 14%) and left ventricular end-systolic dimension (LVDs, 11%) (Fig. 2G ), in combination with the growth of LAX, resulted in an increase in left ventricular end-diastolic volume (LVEDV, 39%) and left ventricular end-systolic volume (LVESV, 30%), respectively (Fig. 2H ), in KOs with hypercholesterolemia. At 16 weeks of age, besides the increase of LVDs and LAX, KOs had the characteristics of a 35% rise in LVESV, and importantly, a decrease in LVEF (11%), FS (13%) (Fig. 2I) , left ventricular posterior wall at end systole (LVPWs, 6%), and left ventricular posterior wall at end diastole (LVPWd, 13%), compared with WTs (Fig. 2J) . Taken together, the LV size expansion and systolic function injury suggested adverse cardiac remodeling in KOs with hypercholesterolemia. No alteration of parameters of heart function was observed in WTs mice treated with AST-IV for 8 weeks (Data not shown). In contrast, the changes of LVEF and FS in AST-HD treated ApoE -/-were significantly improved (LVEF: 60% ± 4.89% vs. 54% ± 5.16%; FS: 31% ± 3.36% vs. 28% ± 3.39%) in comparison with those of KOs. Simultaneously, the decrease of LVDs (11%) and LAX led to a restore in LVESV. No significant improvement in echocardiographic measurements was detected in AST-LD at 16 weeks compared with KOs. WTs at 8 weeks of age. The collagen volume fraction increased over twice in KOs compared with that of WTs at 16 weeks of age, and declined nearly in half in AST-HD animals. Therefore, hypercholesterolemia was prone to developing cardiac fibrosis, and AST-IV administration inhibited fibrosis in hypercholesterolemic heart (Fig. 3A-B) .
The myocardial hypertrophy in hypercholesterolemic ApoE -/-could be induced by the changes of number and size of cardiomyocytes. The survival cardiac myocytes continue to increase in cell size in the form of hypertrophic growth. Therefore, we determined the size and number of ventricular myocytes by immunofluorescence staining with the specific cardiomyocyte marker cTnI. A 19% increase in myocyte size was detected in hypercholesterolemic KOs at 8 weeks of age, whereas myocyte number was almost the same as WTs. At 16 weeks, a greater increase (38%) in myocyte size and a 14% decrease in myocyte number were found in hypercholesterolemic KOs compared with WTs. Myocyte size was markedly suppressed in AST-LD (19%) and AST-HD (27%), and the number of ventricular myocytes was greatly recovered in AST-HD mice compared with KOs ( Fig. 3C-E) .
AST-IV treatment could partly reverse the changes of transcriptional profile in ApoE
−/− mice To examine the transcriptional profile changes in hearts of ApoE −/− and AST-IV treated mice, we studied series of genes linked to the cell cycle, proliferation, senescence, p53-dependent apoptosis pathway and antioxidants. At 16 weeks of age, the mRNA expressions of CDKN1A, CDKN1B, especially CDKN2A, significantly increased in hearts of KOs with hypercholesterolemia. The expressions of CDK4, Cyclin B1, Ki67 and MCM5 were higher in KOs at 16 weeks. Transcriptions for CDKN1A, CDKN1B, CDKN2A, MCM5, Cyclin B1, D1, E1, A2 and CDK4 were decreased in KOs exposed to the low and/or high doses of AST-IV (Fig.  4A) .
In the same way, a series of genes involved in p53-dependent apoptosis pathway, including p53, TP53, Bax, Bcl2, Mcl1, caspase-3, Mdm2, ATM and GADD45A, were studied. Most of the above-mentioned genes transcription was not affected in KOs at 8 weeks of age, except 1.6-fold up-regulation of p53 and 27% down-regulation of Mcl1. However, almost all of genes in p53-dependent apoptosis pathway, excluding Bax and GADD45A, were enhanced more than 2.5 times at transcriptional level in KOs at 16 weeks of age. The transcriptional profiles of these genes were similar in AST-LD and AST-HD groups, which presented marked decreasing mRNA expressions of genes related to p53-dependent apoptosis pathway (Fig.  4B) .
No alteration in gene expressions associated with oxidative stress and antioxidant defense, including Duox1, Srxn1, NOX1, NOX4, GPX2, SOD1, SOD2, was detected at 8 weeks of age. At 16 weeks, most of these genes, except Duox1 and SOD1, were up-regulated at transcriptional level in KOs compared with WTs. However, the mRNA expressions of these genes were decreased in both AST-IV treated groups (Fig. 4C) .
AST-IV treatment could increase the number of Ki67 positive myocytes, and reduce p16
INK4a -positive myocytes in ApoE −/− mice The abnormities of myocyte size and number, and the alterations of related gene expression implied the disturbed states of proliferation, apoptosis and senescence in hypercholesterolemic heart. Thus, we measured the expression of the proliferative related protein Ki67 and the senescent associated protein P16
INK4a by immunofluorescence staining in heart tissue. Cardiac troponin I (cTnI) was co-stained to identify the myocytes. On one hand, the percentage of ki67-positive myocytes of total myocytes in KOs was close to WTs at 8 weeks of age. But it was fewer than nearly four-fifths compared with WTs at 16 weeks, and was increased markedly more than three times after high dose treatment with AST-IV (Fig. 5A-B) . Meanwhile, the percentage of ki67-positive cells in total heart cells within counted vision fields was calculated. The result presented similar variation trend to the percentage of ki67-positive myocytes in our experiments (Data not shown).The decreased protein expression INK4a -positive myocytes were noted in AST-LD (39%) and AST-HD (60%) groups, compared with KOs at 16 weeks (Fig. 5C-D) . Correspondingly, similar changes in the percentage of p16
INK4a -positive cells in total heart cells occurred in the KOs and AST treated mice (Data not shown), which was consistent with its above-mentioned altered gene expression of CDKN2A.
AST-IV treatment could inhibit cell apoptosis in ApoE
−/− mice To determine the impacts of hypercholesterolemia on cardiomyocyte homeostasis, apoptotic cell death was examined further. In KOs group at 8 weeks of age, few myocyte apoptosis was occurred ( < 2%), and it was not differ from WTs. Apoptotic myocytes were detected extensively in KOs, and the percentage of apoptotic myocytes in total myocytes was almost 23-fold higher than that of WTs at 16 weeks. After intervention of AST-IV for 8 weeks, the extent of apoptotic cell death was suppressed in AST-LD (87%) and AST-HD (90%) groups (Fig. 5E-F) . The percentage of apoptotic cells in total cardiac cells displayed similar changes (Fig. 5G) . These data were consistent with the changes of the above-mentioned mRNA expression of p53-dependent apoptosis pathway. Thus, hypercholesterolemia triggered apoptosis in heart, and AST-IV treatment obviously attenuated the apoptotic challenge. 
AST-IV treatment could decrease NOX4 expression in ApoE
−/− mice Hypercholesterolemia is generally associated with oxidative stress and antioxidant defense. NADPH oxidase 4 (NOX4) related to superoxide metabolism, and SOD involved in reactive oxygen species (ROS) metabolism were determined by immunofluorescence staining in this study. As shown in Fig. 3F-I , there were no differences in the percentage of NOX4-positive cells in total heart cells and the positive expression areas of SOD1/2 between KOs and WTs at 8 weeks of age. Nevertheless, at 16 weeks, the percentage of NOX4-positive cells in total heart cells in KOs was higher than WTs, and the positive expression areas of SOD2 in KOs were significantly smaller than that in WTs. No difference was existed in the relative expression of SOD1 between KOs and WTs (Data not shown). After the treatment of AST-IV, the percentage of NOX4-positive cells was significantly decreased in the hearts of AST-LD and AST-HD groups. However, the expressions of SOD1 and SOD2 were not altered in the hearts of AST-LD and AST-HD groups. The results of protein expressions of NOX4, SOD1 and SOD2 were consistent with the relevant mRNA expressions at 8 and 16 weeks, respectively.
Discussion
Hypercholesterolemia is one of contributors to cardiac hypertrophy that occurs in humans. ApoE-deficient mice develop marked hypercholesterolemia and spontaneous atherosclerosis on a normal chow diet, and thus were produced as an animal model for hypercholesterolemia. ApoE, a 34-kD glycoprotein, is a major component of plasma lipoproteins that serves as a ligand for receptor mediated clearance of several classes of lipoproteins from plasma, including chylomicrons, very low density lipoprotein (VLDL), and lipoprotein remnants. ApoE is fundamentally involved in the lipid and cholesterol homeostasis. An increasing number of studies have demonstrated the association between the ApoE genotype and oxidative stress, immunomodulatory/anti-inflammatory properties, mitochondrial and endoplasmic reticulum (ER) stress-related processes [41, 42] . ApoE is highly expressed in the mouse heart, whereas its expression is low in skeletal muscles [43] . The cardiac phenotype in ApoE-deficient mice may be in part due to an impact of loss of the multifunctional nature of the ApoE protein. AST-IV is a kind of pentacyclic triterpenoid. There were few studies focused on the effects of AST-IV on blood lipids. In the present study, we observed AST-IV (1 mg/kg and 10 mg/kg by introperitoneally injection) treatment for 8 weeks could not decrease the concentrations of plasma TC, and LDL-C levels in ApoE −/− mice fed standard diet. This result is not consistent with that of Qin et al [44] , which reported that AST-IV (40 mg/kg by oral gavage) for 12 weeks could down-regulate plasma TG, TC, and LDL-C levels and up-regulate HDL-C level in ApoE −/− mice fed high-fat Western diet. In fructose-fed rats, AST-IV (0.5 mg/kg and 2 mg/kg by introperitoneally injection) treatment for 8 weeks could reduce triglyceride levels [45] . The different doses, methods of administration and duration of AST-IV treatment might be responsible for these inconsistent results. The effects of AST-IV on plasma lipids need to be further confirmed and compared with the present lipid-lowering drugs in clinic, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) inhibitor statins.
Hyperlipidemia may be an early initiator of cardiac remodeling. ApoE −/− mice are more susceptible to cardiac hypertrophy and dysfunction [10, 30] . Compared with agematched wild-type mice, ApoE −/− mice had an increased total ventricular weight, left ventricular weight and HW/BW ratio, a larger LV end diastolic dimension and a smaller LVEF [10, 11, 30] . But several other studies [46, 47] failed to observe cardiac hypertrophy in ApoE −/− mice. In this study, the ApoE −/− mice with hypercholesterolemia presented cardiac remodeling, characterized by increased cardiac weights, dilated chamber and impaired ventricular function, interstitial fibrosis, and increased myocyte size and decreased myocyte number. The aortic stiffness and arterial hypertension in hypercholesterolemia may lead to increased cardiac afterload, thus contribute to cardiac hypertrophy in ApoE -/-mice [48] . Previous studies have identified some common molecular signal transduction pathways and the regulators of pathological cardiac hypertrophic response, which include calcineurin, NFAT, natriuretic peptides, IL-6 cytokine family, Gq/G11 signaling, PI3K, MAPK pathways, RAS, polypeptide growth factors, nitric oxide (NO), TNF-α, peroxisome proliferator activated receptor (PPAR) and JAK/STAT pathway [49] . It has been proved that pathological cardiac hypertrophy can be prevented or reversed by modulating these signaling pathways. In addition to the primary lipid-lowering effect, the statins are speculated to have additional effects on reducing cardiac hypertrophy by inactivating PPAR pathway and attenuating free radical formation [2, 50] . Moreover, blockade of angiotensin signaling via angiotensinconverting enzyme inhibitor or receptor antagonism efficiently restored normal myocardial Li et 
function and cardiac structure during hypercholesterolemia independent of blood pressure change [51, 52] . In this study, the ApoE −/− mice treated with AST-IV presented decrease of ventricular weight, interstitial fibrosis and myocyte size, and preservation of the myocyte number and cardiac systolic function, which implied that AST-IV could prevent cardiac remodeling in ApoE −/− mice with hypercholesterolemia even without lowering blood lipids levels. We postulated that certain common signal transduction pathways and regulators were the targets of AST-IV for its beneficial effects on hypercholesterolemia. Previous studies have confirmed that AST-IV could reverse or delay cardiac remodeling caused by various reasons, such as viral infection [35] , isoproterenol (ISO) [26, 31, 53] and lipopolysaccharide (LPS) [27] . AST-IV protected against ISO-induced cardiac hypertrophy via inhibiting p65 translocation and increasing PPARγ coactivator 1α (PGC-1α) [28] . TLR4/NF-small ka and Cyrillic B signaling pathways were the other targets for the effects of AST-IV against ISOinduced cardiac hypertrophy [26] . AST-IV prevented myocardial fibrosis in coxsackievirus B3-induced dilated cardiomyopathy via down-regulating TGF-β1, Smad4 and p-Smad2/3 expressions [35] . AST-IV attenuated LPS-induced cardiac hypertrophy through inhibiting the activation of Ca 2+ /calcineurin, GATA-4, and the nuclear translocation of NFAT-3 [27] . AST-IV strongly blocked Rheb/mTORC1 signaling pathway and reduced its downstream phospho-S6K levels in myocardial infarction (MI) and transverse aortic constriction (TAC) mice model [30] . AST-IV has shown the ability to attenuate oxidative stress and suppress the activation of the mitochondrial apoptosis via PI3K/Akt signaling pathway [32] . More and more studies showed that AST-IV exerted its cardioprotective function through a number of signaling pathways and multiple target molecules. In this study, we mainly observe the effects of AST-IV on cardiac homeostasis in hypercholesterolemic heart, including the cellular fates of proliferation, senescence and apoptosis. The state of oxidative stress was simultaneously investigated.
The adult myocardium has limited capacity to preserve, renew or rejuvenate itself. The survival, proliferation, and senescence of cardiac cells at rest and following the exposure to different stressors are affected by the changes of local micro-environment. The alterations may act at transcriptional and post-transcriptional levels, and be effectively modulated by natural or synthetic active compounds. In this study, decreased cell proliferation and accelerated senescence in the heart of ApoE −/− mice were noted, which were consistent with the previous research [21] . The coexistence of decreased total number of cardiomyocytes and decreased proliferation marker expression implied that the micro-environmental change induced by hypercholesterolemia weakened the intact proliferative activity of cardiomyocytes. The intervention of AST-IV effectively increased the percentages of ki67-positive myocytes and ki67-positive cells in the heart of hypercholesterolemic mice. The total number of cardiomyocytes was maintained by AST-IV treatment. The results suggested that AST-IV functioned as a cardiac regenerator.
The transcriptional levels of genes related to cell cycle were analyzed in this study. CDKs are serine-threonine kinases, which become active upon formation of a complex with the corresponding cyclin. Cell cycle progression requires accurate CDK-cyclin complexes formation at the corresponding checkpoints. The CDK4-Cyclin D complex plays the most crucial role at the G1/S-phase transition. Further the main active complex at the G2/M transition is cdc2-Cyclin E. CDKIs are negative regulators of CDKs. The expressions of cyclins and the corresponding CDKs are significantly down-regulated in hearts afterbirth, accompanied by up-regulated expression of CDKIs. Whether alteration of these regulators causes the decrease in myocyte proliferation afterbirth or vice versa remains a mystery. We demonstrated that the mild change of expressions of CDKs and cyclins in this study, except cyclin B1 and cdc2. However, the expression of CDKIs, including p21, p27 and p16, obviously increased in hypercholesterolemic hearts, functioned dominantly, and involved in cell cycle arrest. The treatment of AST-IV significantly down-regulated the expression of CDKIs, and thus might promote the myocyte proliferation.
Cellular senescence is an anti-proliferative process of protecting irreversible cell cycle arrest in certain pathologic conditions induced by genetic and/or epigenetic abnormalities.
The senescent cells cease to cycle progression, consequently lead to inability of maintenance of tissue homeostasis. p16 belongs to INK4 family of CDKIs, and selectively blocks CDK4/6-Cyclin D complex formation and subsequent enzymatic activity. The expression of p16 has been suggested to be low in young adult hearts and increase in aged hearts. Thus, p16 is regarded as one of markers of cellular aging or senescence. Tumor suppressor p53 can facilitate cell cycle arrest and senescence program in cells in response to stress [54] . The high expressions of p16 and p53 hamper the resuming cell cycle progression for a senescent cell [55] . Myocyte senescence is associated with oxidative stress, chronic adrenergic signaling, renin-angiotensin-aldosterone signaling (RAAS) and mTORC pathway [55] . The mitochondrial functional impairment induces oxidative stress, serves as a primary inciting stimulus for transition into senescence. The cardiomyocytes with hyper-activation of the RAAS developed an aged phenotype. Over-stimulation of mTORC1 pathway through growth factors promoted cardiac senescence. Previous studies proved that AST-IV could resist the cardiac adrenergic [28] and angiotensin stimulation [56] , inhibit mTORC1 [30] , and thus protect against cardiac remodeling. In this study, we found that the hypercholesterolemic heart presented high expressions of p16 and p53, which could be reversed after AST-IV treatment. It suggested that AST-IV could impede the process of cardiac senescence.
Enhanced apoptosis is another reason for the decreased total number of cardiomyocytes in pathologic conditions. Apoptosis is a programmed cell death mechanism which is essential for the maintenance of tissue homeostasis. One of the major apoptosis signaling pathways involves the p53 tumor suppressor. Cellular p53 levels are low or undetectable under normal conditions by continuous ubiquitylation (e.g. MDM2) and subsequent degradation, and increased by post-translational modifications (e.g. phosphorylated by ATM) under stress signals stimulation. As a nuclear transcription factor, activated p53 enhanced expression of a number of downstream genes containing p53-binding sites within their regulatory regions [57] . p53 induces cell apoptosis by activating mitochondrial-and death receptor-mediated caspase-dependent apoptotic pathways. The mitochondrial pathway is mainly dominated by p53 effector Bcl-2 family of protein (e.g. Bax/Bcl-2). We found that the expressions of gene associated with p53-apoptosis pathway, including TP53, Bax, Bcl2, Mcl1, caspase 3, MDM2, and ATM, were changed in heart of ApoE −/− mice. These results were consistent with the recent study [58] , which demonstrated that the higher expressions of p53 and caspase-3/9 in heart of ApoE −/− mice. We also demonstrated that the percentages of apoptotic myocytes and apoptotic cells in the heart of ApoE -/-mice were significantly higher than those of wild-type mice at 16 weeks, and were suppressed after the treatment of AST-IV. The transcriptional changes of p53-apoptotic pathway in hypercholesterolemia were also reversed after AST-IV treatment. Previous studies reported that AST-IV exerted anti-apoptosis effect on cardiomyocyte by attenuating oxidative stress and calpain-1 activation [31] , inhibiting the activation of mitochondrial apoptotic pathway via PI3K/Akt pathway [32] . Whether p53-dependent apoptosis pathway is another target pathway for the anti-apoptosis effect of AST-IV needs to be further investigated.
There is a fine-tuned balance between oxidant and anti-oxidant molecules in cells. Enzymatic sources for ROS formation include the mitochondrial respiratory chain, NADPH oxidases (NOX), and so on. The antioxidant systems include enzymes (e.g. SOD, catalase) and endogenous non-enzymatic antioxidant molecules (e.g. NO). Therefore, the excess formation of ROS by oxidant systems and/or insufficient removal capacity of anti-oxidant systems results in oxidative stress. The increased ROS production in the hypercholesterolemic heart was mainly caused by increased NOX activity, especially NOX4, which can be related to transcriptional, posttranscriptional, or epigenetic regulation of NOX4 expression [16] . Decreased cardiac expression and activity of antioxidants, such as SOD, is another possible explanation for increased ROS in hypercholesterolemic hearts. The precise molecular mechanism by which hypercholesterolemia up-regulates myocardial oxidant enzymes and down-regulates antioxidant enzymes remain to be elucidated. It was reported that excess production of ROS in ApoE −/− mice triggered several signalings such as lipid oxidation, DNA damage, senescence and production of pro-inflammatory substances [48] . Accumulating studies suggested that elevated oxidative stress played an important role in hypercholesterolemia-induced cardiac complications. Therefore, modulation of hypercholesterolemia-induced myocardial oxidative stress is a rational approach to prevent or treat cardiac consequences. In this study, we confirmed that the expression of NOX4 increased and SOD2 decreased in the hearts of ApoE -/-mice, which could be reversed after the treatment of AST-IV. AST-IV alleviated oxidative stress in many pathological conditions [59] by inhibiting oxidants (e.g. NOXs) and/or strengthening antioxidants (e.g. SOD).
Conclusions
In summary, our results indicated that ApoE −/− mice with hypercholesterolemia presented cardiac remodeling, characterized by increased cardiac weights, dilated chamber and impaired ventricular function, cardiac fibrosis, increased myocyte size and decreased myocyte number. Meanwhile, the cardiac homeostasis, including cell proliferation, senescence and apoptosis, and oxidative stress were changed in hypercholesterolemic heart. Neither 1 mg/kg nor 10 mg/kg AST-IV treatment lasting for 8 weeks could reduce the plasma lipids levels of ApoE -/-mice. But the mice with high dose AST-IV treatment presented better effects on preventing cardiac remodeling, maintaining cardiac homeostasis, inhibiting senescence and apoptosis, and reducing oxidative stress. 
